Lucid Diagnostics (LUCD) vs Sera Prognostics (SERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sera Prognostics (SERA) has outperformed Lucid Diagnostics (LUCD) over the past year, losing 35.9% versus a loss of 46.7%. Over five years, SERA leads with a -81.4% price change compared with -93.0% for LUCD. Lucid Diagnostics is the larger company by market cap ($120.7 million vs $82.8 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUCD | SERA |
|---|---|---|
| Share price | $0.632 | $2.10 |
| Market cap | $120.68M | $82.80M |
| 1-day change | -2.78% | +3.91% |
| YTD return | -40.36% | -31.53% |
| 1-year return | -46.71% | -35.87% |
| 5-year return | -93.05% | -81.38% |
| EPS (TTM) | $-0.44 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.63 | $3.95 |
| 52-week low | $0.50 | $1.56 |
| Distance from 52-week high | -61.20% | -46.86% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +532.91% | +162.03% |
| Average volume | 1.35M | 27.84K |
| Shares outstanding | 190.95M | 38.48M |
| Employees | 82 | 71 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SERA has outperformed LUCD by 10.8 percentage points over the past year.
About Lucid Diagnostics
LUCD stock →Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
Health Care · Medical/Dental Instruments · 82 employees
About Sera Prognostics
SERA stock →Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
Health Care · Medical Specialities · 71 employees
LUCD vs SERA FAQ
Which is bigger, Lucid Diagnostics or Sera Prognostics?
Lucid Diagnostics (LUCD) is larger, with a market capitalization of $120.68M compared with $82.80M for Sera Prognostics (SERA).
Which stock has performed better over the past year, LUCD or SERA?
SERA returned -35.87% over the past 12 months, compared with -46.71% for LUCD (price return, excluding dividends). Past performance does not predict future results.
Are Lucid Diagnostics and Sera Prognostics in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Lucid Diagnostics and Medical Specialities for Sera Prognostics.